Neuca recorded PLN 25.55 million of consolidated net profit in Q4 2021 compared to PLN 18.6 million profit a year earlier, the company said in the report. The operating profit was PLN 38.01m, compared to PLN 43.06m profit a year earlier. EBITDA was PLN 60.06 million compared to PLN 60.45 million a year earlier. Consolidated sales revenues amounted to PLN 2,681.46 million in Q4 2021 compared to PLN 2,392.57 million a year earlier.
“Despite the still difficult epidemic situation in Poland, we observe a stabilization of the drug distribution market in which Neuca operates. The retail pharmacy and wholesale markets increased their value by over 6% year on year, the value of the wholesale market reached PLN 34 billion. After lower dynamics in 2020, we see a return to market dynamics before the pandemic period. The segment of independent pharmacies, strategic for the Neuca Group, is doing better and better. It is slowing down the pace of decline in the segment of independent pharmacies, which last year reached the lowest, never-before-seen level (-0.63 percentage points y / y). This proves the growing balance between the segments of independent and chain pharmacies on the drug distribution market, ”wrote President Piotr Sucharski in a letter to shareholders.
The Neuca Group is a market leader in the wholesale of drugs. The total share of the Neuca group companies in the domestic pharmacy wholesale market at the end of 2021 was 31.7%.